eGenesis lands $191m to advance xenotransplantation into clinical trials
eGenesis secures $191 million to advance genetically edited pig kidneys for human transplantation, addressing the organ shortage crisis. The company's EGEN-2784 candidate, featuring genetic modifications to prevent rejection and viral transmission, achieved the world's first successful transplant of a genetically modified porcine kidney in a human in 2024.
Reference News
eGenesis, a xenotransplantation pioneer, has secured $191 million in Series D financing led by Lux Capital to advance its genetically engineered porcine kidney transplant program. The company announced the world's first successful porcine kidney transplant in a living patient in March 2024, under FDA authorization. The financing aims to support formal clinical trials and address the global organ shortage crisis.
eGenesis secures $191 million to advance genetically edited pig kidneys for human transplantation, addressing the organ shortage crisis. The company's EGEN-2784 candidate, featuring genetic modifications to prevent rejection and viral transmission, achieved the world's first successful transplant of a genetically modified porcine kidney in a human in 2024.